OBJECTIVE: Vitamin D has various actions in skeletal muscle. The purpose of this study was to compare lower-limb muscle size and strength in hemodialysis (HD) patients being treated with 1,25-dihydroxyvitamin D (calcitriol) or a 1,25-dihydroxyvitamin D analogue (paricalcitol) with lower-limb muscle size and strength in HD patients who were receiving none. DESIGN: This was a retrospective, cross-sectional study. SETTING: This study was performed in outpatient HD centers. PATIENTS: Hemodialysis patients receiving calcitriol or paricalcitol (active vitamin D) for control of secondary hyperparathyroidism (VitD, n = 49) were compared with HD patients who were not (n = 30). MAIN OUTCOME MEASURES: The main outcome measures included the cross-sectional areas (CSAs) of the thigh and tibialis anterior muscles by magnetic resonance imaging, and three measures of strength: the three-repetition maximum (3RM) for knee extension (isotonic), the peak torque of knee extensors (isokinetic), and maximal voluntary contraction of the ankle dorsiflexor muscles (isometric). RESULTS: There were no differences in age, weight, dialysis vintage, or intact parathyroid hormone levels between groups, although serum albumin was higher in the VitD group (P < .05). Patients in the VitD group had a larger thigh-muscle CSA (P < .05) and were stronger across all strength measures (P < .05) after controlling for age and gender (by analysis of covariance). When all analyses were subsequently adjusted for serum albumin concentration, only the difference in 3RM knee-extension strength lost significance. There were no significant differences in any measurements between patients who received calcitriol or paricalcitol. CONCLUSION: Treatment with active vitamin D was associated with greater muscle size and strength in this cohort of HD patients.
OBJECTIVE:Vitamin D has various actions in skeletal muscle. The purpose of this study was to compare lower-limb muscle size and strength in hemodialysis (HD) patients being treated with 1,25-dihydroxyvitamin D (calcitriol) or a 1,25-dihydroxyvitamin D analogue (paricalcitol) with lower-limb muscle size and strength in HDpatients who were receiving none. DESIGN: This was a retrospective, cross-sectional study. SETTING: This study was performed in outpatientHD centers. PATIENTS: Hemodialysis patients receiving calcitriol or paricalcitol (active vitamin D) for control of secondary hyperparathyroidism (VitD, n = 49) were compared with HDpatients who were not (n = 30). MAIN OUTCOME MEASURES: The main outcome measures included the cross-sectional areas (CSAs) of the thigh and tibialis anterior muscles by magnetic resonance imaging, and three measures of strength: the three-repetition maximum (3RM) for knee extension (isotonic), the peak torque of knee extensors (isokinetic), and maximal voluntary contraction of the ankle dorsiflexor muscles (isometric). RESULTS: There were no differences in age, weight, dialysis vintage, or intact parathyroid hormone levels between groups, although serum albumin was higher in the VitD group (P < .05). Patients in the VitD group had a larger thigh-muscle CSA (P < .05) and were stronger across all strength measures (P < .05) after controlling for age and gender (by analysis of covariance). When all analyses were subsequently adjusted for serum albumin concentration, only the difference in 3RM knee-extension strength lost significance. There were no significant differences in any measurements between patients who received calcitriol or paricalcitol. CONCLUSION: Treatment with active vitamin D was associated with greater muscle size and strength in this cohort of HDpatients.
Authors: A St John; M B Thomas; C P Davies; B Mullan; I Dick; B Hutchison; A van der Schaff; R L Prince Journal: Nephron Date: 1992 Impact factor: 2.847
Authors: H A Bischoff; H B Stahelin; N Urscheler; R Ehrsam; R Vonthein; P Perrig-Chiello; A Tyndall; R Theiler Journal: Arch Phys Med Rehabil Date: 1999-01 Impact factor: 3.966
Authors: William G Petchey; Erin J Howden; David W Johnson; Carmel M Hawley; Thomas Marwick; Nicole M Isbel Journal: Clin J Am Soc Nephrol Date: 2010-12-16 Impact factor: 8.237
Authors: Janwillem Testerink; Richard T Jaspers; Jörn Rittweger; Arnold de Haan; Hans Degens Journal: J Physiol Sci Date: 2011-09-11 Impact factor: 2.781